Zobrazeno 1 - 10
of 286
pro vyhledávání: '"Mark S. Cragg"'
Autor:
Silvia Redondo-García, Christopher Barritt, Charys Papagregoriou, Muchaala Yeboah, Björn Frendeus, Mark S. Cragg, Ali Roghanian
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Human leukocyte immunoglobulin (Ig)-like receptors (LILR) are a family of 11 innate immunomodulatory receptors, primarily expressed on lymphoid and myeloid cells. LILRs are either activating (LILRA) or inhibitory (LILRB) depending on their associated
Externí odkaz:
https://doaj.org/article/b2d939679c3440e4a96adf5e239476b6
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The tumor necrosis factor superfamily (TNFSF) and their receptors (TNFRSF) are important regulators of the immune system, mediating proliferation, survival, differentiation, and function of immune cells. As a result, their targeting for immunotherapy
Externí odkaz:
https://doaj.org/article/8b5755ed18974dd39aa3959d301a8ad5
Autor:
Khiyam Hussain, Rena Liu, Rosanna C. G. Smith, Kri T. J. Müller, Mohammadmersad Ghorbani, Sofia Macari, Kirstie L. S. Cleary, Robert J. Oldham, Russell B. Foxall, Sonya James, Steven G. Booth, Tom Murray, Lekh N. Dahal, Chantal E. Hargreaves, Robert S. Kemp, Jemma Longley, James Douglas, Hannah Markham, Serena J. Chee, Richard J. Stopforth, Ali Roghanian, Matthew J. Carter, Christian H. Ottensmeier, Bjorn Frendéus, Ramsey I. Cutress, Ruth R. French, Martin J. Glennie, Jonathan C. Strefford, Stephen M. Thirdborough, Stephen A. Beers, Mark S. Cragg
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-32 (2022)
Abstract Background Hypoxia is a hallmark of the tumor microenvironment (TME) and in addition to altering metabolism in cancer cells, it transforms tumor-associated stromal cells. Within the tumor stromal cell compartment, tumor-associated macrophage
Externí odkaz:
https://doaj.org/article/4a2581bb496d4f649850cb54190883b9
Autor:
Franziska Heckel, Anna H. Turaj, Hayden Fisher, H. T. Claude Chan, Michael J. E. Marshall, Osman Dadas, Christine A. Penfold, Tatyana Inzhelevskaya, C. Ian Mockridge, Diego Alvarado, Ivo Tews, Tibor Keler, Stephen A. Beers, Mark S. Cragg, Sean H. Lim
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-15 (2022)
Agonistic CD27 monoclonal antibodies can be used to enhance the efficacy of depleting antibodies such as anti-CTLA-4 in a colon adenocarcinoma tumour model. CD27 antibody agonism is dependent on isotype and epitope specificity.
Externí odkaz:
https://doaj.org/article/f7e2de2c168f4f2984754369dc482291
Autor:
Joshua M. Sopp, Shirley J. Peters, Tania F. Rowley, Robert J. Oldham, Sonya James, Ian Mockridge, Ruth R. French, Alison Turner, Stephen A. Beers, David P. Humphreys, Mark S. Cragg
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Sopp et al describe an approach, which exploits the tailpiece of the naturally multimeric IgM to augment hexamerisation of IgG. Their approach provides a newly engineered format of antibodies for promoting hexamerisation and enhanced complement-depen
Externí odkaz:
https://doaj.org/article/26ae9b2bf9f1415f9ed90dfd8fef8201
Autor:
Johannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, Billy Michael Chelliah Jebaraj, Sandra Robrecht, Julia Krzykalla, Heng Pan, Adam Giza, Gulnara Akylzhanova, Karlheinz Holzmann, Annika Scheffold, Harvey E. Johnston, Ru-Fang Yeh, Tetyana Klymenko, Eugen Tausch, Barbara Eichhorst, Lars Bullinger, Kirsten Fischer, Martin Weisser, Tadeusz Robak, Christof Schneider, John Gribben, Lekh N. Dahal, Mathew J. Carter, Olivier Elemento, Dan A. Landau, Donna S. Neuberg, Mark S. Cragg, Axel Benner, Michael Hallek, Catherine J. Wu, Hartmut Döhner, Stephan Stilgenbauer, Daniel Mertens
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
Chronic lymphocytic leukemia has been studied using multiple levels of omics data. Here, the authors use exome sequencing, SNP, protein and gene expression data to identify distinct biologic tumor subtypes with heterogeneous prognostic impact after c
Externí odkaz:
https://doaj.org/article/fc98052a777c445bb5de9e2a3b17c607
Autor:
Xiaojie Yu, Sonya James, James H. Felce, Blanka Kellermayer, David A. Johnston, H. T. Claude Chan, Christine A. Penfold, Jinny Kim, Tatyana Inzhelevskaya, C. Ian Mockridge, Yasunori Watanabe, Max Crispin, Ruth R. French, Patrick J. Duriez, Leon R. Douglas, Martin J. Glennie, Mark S. Cragg
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-15 (2021)
Yu et al examined a panel of both experimental and clinically-relevant TNF agonists in order to advance our understanding of the mechanisms underlying their varying activities and anti-tumor responses. They demonstrated that agonists with greater act
Externí odkaz:
https://doaj.org/article/497b996aa1574d6a946f5ee6787fec3f
Autor:
Emily R. Webb, Silvia Lanati, Carol Wareham, Alistair Easton, Stuart N. Dunn, Tatyana Inzhelevskaya, Freja M. Sadler, Sonya James, Margaret Ashton-Key, Mark S. Cragg, Stephen A. Beers, Juliet C. Gray
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-17 (2020)
Abstract Immunotherapy offers a potentially less toxic, more tumor-specific treatment for neuroblastoma than conventional cytotoxic therapies. Accurate and reproducible immune competent preclinical models are key to understanding mechanisms of action
Externí odkaz:
https://doaj.org/article/1cd179c8bd0e4a0ba1a1db6fa9ea0186
Autor:
Jack G. Fisher, Christopher J. Walker, Amber DP. Doyle, Peter WM. Johnson, Francesco Forconi, Mark S. Cragg, Yosef Landesman, Salim. I. Khakoo, Matthew D. Blunt
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Selinexor is an FDA approved selective inhibitor of the nuclear export protein exportin-1 (XPO1) and causes specific cancer cell death via nuclear accumulation of tumor suppressor proteins. Design of rational studies for the use of selinexor in combi
Externí odkaz:
https://doaj.org/article/3bc2ec99a6694182a242490b99350987
Publikováno v:
iScience, Vol 24, Iss 10, Pp 103131- (2021)
Summary: Current influenza vaccines do not typically confer cross-protection against antigenically mismatched strains. To develop vaccines conferring broader cross-protection, recent evidence indicates the crucial role of both cross-reactive antibodi
Externí odkaz:
https://doaj.org/article/7a139b1078664439871b2b0f8bed7be3